Clinic statistics on RLT 177Lu-PSMA
As many trials with 177Lu-PSMA radioligand therapy (RLT) have demonstrated, a reduction of PSA of over 50% leads to statistically significant increase in overall survival. Our clinic’s results show the reproducibility of this data. After 3 sessions of 177Lu-PSMA PSA decreases by an average of 68%. Preserving remissions and increasing quality of life of our patients remain our goals.
Pluvicto® approval by EMA
Pluvicto® approval by EMA
Following FDA approval in March 2022, European Medicines Agency (EMA) also approved Pluvicto® (lutetium (177Lu) vipivotide tetraxetan) of Novartis in December 2022 for targeted radioligand treatment of progressive PSMA–positive metastatic castration-resistant prostate cancer. The EMA approval is based on the results from the Phase III VISION trial, in which “radioligand therapy with 177Lu-PSMA-617 prolonged radiographic progression-free survival and overall survival when added to standard care in patients with advanced PSMA-positive metastatic castration-resistant prostate cancer”[1]. “The lutetium-177-PSMA was developed by the German Cancer Research Center (DKFZ) in cooperation with Heidelberg University Hospital and Heidelberg University.”[2]
[1] https://www.nejm.org/doi/full/10.1056/nejmoa2107322
[2] https://www.krebsinformationsdienst.de/aktuelles/2022/news059-metastasierter-prostatakrebs-zulassung-pluvicto-lutetium-177-psma-617-europa.php
Prof.Dr. Haug awarded The European Awards in Medicine in the field of nuclear medicine
The European Award in Nuclear Medicine 2022
We are thrilled and proud to share that our colleague Prof.Dr. Alexander Haug has been awarded The European Awards in Medicine 2022 in the field of nuclear medicine.
Interview with a patient
Interview with a patient, September 2022
The patient A.G., 72 y.o., a molecular biologist himself, was diagnosed with metastatic prostate cancer in September 2018. After the conventional standard-of-care treatment (chemo- and antihormonal therapy) there were still residues of the primary tumour in the prostate, and lymph nodes and bone metastases. Up to date he has gone through 9 sessions (3 cycles) of 177Lu-PSMA therapy in the course of three years, initiating a new cycle once a routine control 68Ga-PSMA PET/CT detected PSMA expressing cancer lesions. The therapy has been extremely successful for A.G.: high response and hardly any side effects. Targeted radioligand therapy brings us much closer to the goal of making prostate cancer just another treatable chronic disease, at the same time preserving a decent quality of life, much like e.g. diabetes.
Manufacturing personalized radioligands in the laboratory
Manufacturing personalized radioligands in the laboratory
FAPi-based targeted theranostics for treating radioiodine-refractory differentiated thyroid cancer
FAPi-based targeted theranostics for treating radioiodine-refractory differentiated thyroid cancer
The study of FAPi-based lutetium-177 therapy in the All India Institute Of Medical Sciences in New Delhi was meant to investigate the therapeutic efficacy and safety of 177Lu-DOTAGA.(SA.FAPi)2 in RR-DTC patients. 15 heavily pre-treated (min 2 lines of prior treatment with lenvatinib and/or sorafenib) patients with the disease progression were selected based on FAPi PET/CT. An average of 3 sessions of 2 GBq each was administered in an 8-week interval.
TheraP study comparing radioligand treatment with 177Lu-PSMA-617 to the chemotherapy using cabazitaxel
Trial comparing radioligand treatment with 177Lu-PSMA-617 to the chemotherapy using cabazitaxel in treating mCRPC
TheraP, a phase II trial comparing radioligand treatment with 177Lu-PSMA-617 to the chemotherapy using cabazitaxel was finalized with 177Lu-PSMA demonstrating a clear advantage over the chemotherapy.
EAU updates its Prostate Cancer Guidelines
EAU updates its Prostate Cancer Guidelines
After the conclusion of the Vision trials the urological associations start gradually adjusting their Prostate Cancer guidelines, both in diagnostics and treatment. EAU now strongly recommends:
- PSMA PET/CT (with gallium-68 or fluorine-18) as a more accurate diagnostic method than CT and bone scan for the staging of high-risk prostate cancer (PSA > 20 ng/mL, or GS > 7, or clinically palpable tumour in both lobes (cT2c)), and
- 177Lu-PSMA as a therapy of choice for pre-treated (ADT) mCRPC patients with one or more metastatic lesions, highly expressing PSMA on the diagnostic radiolabelled PSMA PET/CT scan.
https://uroweb.org/guidelines/prostate-cancer/summary-of-changes
Both are available in our institution. Make your appointment now.
FAPI
Nuclear theranostics: what’s next?
While theranostics has immensely improved overall survival and quality of life of NET and prostate cancer patients and is increasingly becoming mainstream, the science is tirelessly working on the next big thing – pan-cancer theranostics based on fibroblast activation protein (FAP) found in the cancer-associated fibroblasts (CAF). With many widespread cancers in question, this would be truly revolutionary. First-in-human PET/CT studies of 68Ga-FAPI have demonstrated excellent results. A tracer derivative better suited for the therapeutical ends is within reach.
Bone metastases, prostate cancer and theranostics
Bone metastases, prostate cancer and theranostics
Bone metastases are a common secondary cancer of many cancer types, such as breast (70%), prostate (85%), lung and kidney cancer (40%), due to the unique bone microenvironment. Tumors mostly metastasize to axial skeleton (i.e. bones of the trunk and pelvis) rather than to appendicular skeleton (limbs and girdles) along the distribution of the red bone marrow.
Joint EANM procedure guideline / SNMMI procedure standard for prostate cancer imaging 2.0
Joint EANM procedure guideline / SNMMI procedure standard for prostate cancer imaging 2.0
EANM and SNMMI have updated their joint PSMA PET/CT procedure guideline for prostate cancer imaging with the most recent information. “This guideline supports physicians in recommending, acquiring, interpreting and reporting the results of PSMA-ligand PET/CT for initial diagnosis, staging and restaging of prostate cancer. … This document reports on patient selection, PET/CT acquisition, image interpretation and written summary of the clinical report. Specific advice is given for the most common PSMA radioligands available and for clinical scenarios with frequent use of PET/CT, including staging, restaging and assessment for suitability of PSMA RLT.”
NET Patient Education Conference of NET Research Foundation on Theranostics (PRRT)
Video: Nuclear imaging 68Ga-DOTATATE and PRRT 177Lu-DOTATATE explained (English)
NET Patient Education Conference of NET Research Foundation on Theranostics (PRRT), Stanford, US, March 2017